The Anti-Global, Specialist Strategy: Why Bayer's Choice Might Be Right for Other Pharmas
Executive Summary
Bayer's retreat from the global, primary-care stage into the mid-sized, regionally-focused specialist player arena was forced upon it by its own particular set of challenges. But other drug firms facing similar issues should take note: globalism may not be the best way forward in today's environment.
You may also be interested in...
Novo-ZymoGenetics: The Next Roche-Genentech?
Novo Nordisk's decision to spin off ZymoGenetics in 2000 was 100% inspired by Roche's hands-off relationship with Genentech. The parent claims Zymo's R&D productivity has since increased; its recent ex-US deal with Bayer-Schering on recombinant thrombin proves that Zymo has certainly grown up and left home.
Co-Promotes: A Marketplace Reality, But Do They Make Sense?
Co-promotions are a hallmark of today's licensing deals as biotechs try to secure their future growth. But do they make sense--for the product, or for the partners?
Co-Promotes: A Marketplace Reality, But Do They Make Sense?
Co-promotions are a hallmark of today's licensing deals as biotechs try to secure their future growth. But do they make sense--for the product, or for the partners?
Need a specific report? 1000+ reports available
Buy Reports